KRAS and neoplasm: ,2 Unlike pancreatic ductal adenocarcinoma (PDAC), where Kirsten rat sarcoma viral oncogene homolog (KRAS) gene mutations dominate >90% prevalence, KRAS mutations are rare in well-differentiated PNETs but are a hallmark of PNECs, yet their mechanistic contributions to tumor progression remain enigmatic.3